National Estimates of Mental Health Needs Among Adults With Self-Reported CKD in the United States

• Published in: Kidney international reports Vol. 7; no. 7; pp. 1630 - 1642
• Main Authors: Wilk, Adam S., Hu, Ju-Chen, Chehal, Puneet, Yarbrough, Courtney R., Ji, Xu, Cummings, Janet R.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.07.2022; Elsevier
• Subjects: chronic kidney disease; Clinical Research; mental health treatment; mental illness; mental illness; chronic kidney disease; mental health treatment
• ISSN: 2468-0249; 2468-0249
• DOI: 10.1016/j.ekir.2022.04.088

Among adults with chronic kidney disease (CKD), comorbid mental illness is associated with poorer health outcomes and can impede access to transplantation. We provide the first US nationally representative estimates of the prevalence of mental illness and mental health (MH) treatment receipt among adults with self-reported CKD. Using 2015 to 2019 National Survey on Drug Use and Health (NSDUH) data, we conducted an observational study of 152,069 adults (age ≥22 years) reporting CKD (n = 2544), with no reported chronic conditions (n = 117,235), or reporting hypertension (HTN) or diabetes mellitus (DM) but not CKD (HTN/DM, n = 32,290). We compared prevalence of (past-year) any mental illness, serious mental illness (SMI), MH treatment, and unmet MH care needs across the groups using logistic regression models. Approximately 26.6% of US adults reporting CKD also had mental illness, including 7.1% with SMI. When adjusting for individual characteristics, adults reporting CKD were 15.4 percentage points (PPs) and 7.3 PPs more likely than adults reporting no chronic conditions or HTN/DM to have any mental illness (P < 0.001) and 5.6 PPs (P < 0.001) and 2.2 PPs (P = 0.01) more likely to have SMI, respectively. Adults reporting CKD were also more likely to receive any MH treatment (21% vs. 12%, 18%, respectively) and to have unmet MH care needs (6% vs. 3%, 5%, respectively). Mental illness is common among US adults reporting CKD. Enhanced management of MH needs could improve treatment outcomes and quality-of-life downstream. [Display omitted]